Isavuconazole therapy protects immunosuppressed mice from mucormycosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 4, 2014, Pages 2450-2453

  Luo, Guanpingsheng ^a   Gebremariam, Teclegiorgis ^a   Lee, Hongkyu ^a   Edwards Jr , John E ^a,b   Kovanda, Laura ^c   Ibrahim, Ashraf S ^a,b  

^a St John's Cardiovascular Research Center   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CORTISONE; CORTISONE ACETATE; CYCLOPHOSPHAMIDE; ISAVUCONAZONIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; IN VITRO STUDY; IN VIVO STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; MUCORMYCOSIS; NONHUMAN; PRIORITY JOURNAL; RHIZOPUS; RHIZOPUS DELEMAR; SURVIVAL TIME;

ANIMALS; ANTIFUNGAL AGENTS; IMMUNOSUPPRESSION; MALE; MICE; MICE, INBRED ICR; MUCORMYCOSIS; NITRILES; PYRIDINES; TRIAZOLES;

EID: 84896930341     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02301-13     Document Type: Article

References (34)

1. Chakrabarti A, Chatterjee SS, Das A, Panda N, Shivaprakash MR, Kaur A, Varma SC, Singhi S, Bhansali A, Sakhuja V. 2009. Invasive zygomycosis in India: experience in a tertiary care hospital. Postgrad. Med. J. 85:573-581. http://dx.doi.org/10.1136/pgmj.2008.076463.
2. Marr KA, Carter RA, Crippa F, Wald A, Corey L. 2002. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin. Infect. Dis. 34:909-917. http://dx.doi.org/10.1086/339202. (Pubitemid 34229758)
3. Rammaert B, Lanternier F, Zahar JR, Dannaoui E, Bougnoux ME, Lecuit M, Lortholary O. 2012. Healthcare-associated mucormycosis. Clin. Infect. Dis. 54(Suppl 1):S44-S54. http://dx.doi.org/10.1093/cid/cir867.
4. Petrikkos G, Skiada A, Lortholary O, Roilides E, Walsh TJ, Kontoyiannis DP. 2012. Epidemiology and clinical manifestations of mucormycosis. Clin. Infect. Dis. 54(Suppl 1):S23-S34. http://dx.doi.org/10.1093/cid/cir866.
5. Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, Etienne K, Deak E, Derado G, Shieh WJ, Drew C, Zaki S, Sugerman D, Gade L, Thompson EH, Sutton DA, Engelthaler DM, Schupp JM, Brandt ME, Harris JR, Lockhart SR, Turabelidze G, Park BJ. 2012. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N. Engl. J. Med. 367:2214-2225. http://dx.doi.org/10.1056/NEJMoa1204781.
6. Warkentien T, Rodriguez C, Lloyd B, Wells J, Weintrob A, Dunne JR, Ganesan A, Li P, Bradley W, Gaskins LJ, Seillier-Moiseiwitsch F, Murray CK, Millar EV, Keenan B, Paolino K, Fleming M, Hospenthal DR, Wortmann GW, Landrum ML, Kortepeter MG, Tribble DR. 2012. Invasive mold infections following combat-related injuries. Clin. Infect. Dis. 55:1441-1449. http://dx.doi.org/10. 1093/cid/cis749.
7. Gleissner B, Schilling A, Anagnostopolous I, Siehl I, Thiel E. 2004. Improved outcome of zygomycosis in patients with hematological diseases? Leuk. Lymphoma 45:1351-1360. http://dx.doi.org/10.1080/10428190310001653691. (Pubitemid 38701909)
8. Ibrahim AS, Edwards JE, Jr, Filler SG, Spellberg B. 2011. Mucormycosis and entomophthoromycosis (zygomycosis), p 265-280. In Kauffman CA, Pappas PG, Sobel JD, Dismukes WE (ed), Essentials of clinical mycology, 2nd ed. Springer, New York, NY.
9. Kauffman CA. 2004. Zygomycosis: reemergence of an old pathogen. Clin. Infect. Dis. 39:588-590. http://dx.doi.org/10.1086/422729. (Pubitemid 39120941)
10. Kontoyiannis DP, Wessel VC, Bodey GP, Rolston KV. 2000. Zygomycosis in the 1990s in a tertiary-care cancer center. Clin. Infect. Dis. 30:851-856. http://dx.doi.org/10.1086/313803. (Pubitemid 32250321)
11. Husain S, Alexander BD, Munoz P, Avery RK, Houston S, Pruett T, Jacobs R, Dominguez EA, Tollemar JG, Baumgarten K, Yu CM, Wagener MM, Linden P, Kusne S, Singh N. 2003. Opportunistic mycelial fungal infections in organ transplant recipients: emerging importance of non-Aspergillus mycelial fungi. Clin. Infect. Dis. 37:221-229. http://dx.doi.org/10.1086/375822. (Pubitemid 36930353)
12. Perkhofer S, Lechner V, Lass-Florl C. 2009. In vitro activity of isavuconazole against Aspergillus species and zygomycetes according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob. Agents Chemother. 53:1645-1647. http://dx.doi.org/10.1128/AAC.01530- 08.
13. Warn PA, Sharp A, Denning DW. 2006. In vitro activity of a new triazole BAL4815, the active component of BAL8557 (the water-soluble prodrug), against Aspergillus spp. J. Antimicrob. Chemother. 57:135-138. http://dx.doi.org/10. 1093/jac/dki399. (Pubitemid 43057070)
14. Warn PA, Sharp A, Mosquera J, Spickermann J, Schmitt-Hoffmann A, Heep M, Denning DW. 2006. Comparative in vivo activity of BAL4815, the active component of the prodrug BAL8557, in a neutropenic murine model of disseminated Aspergillus flavus. J. Antimicrob. Chemother. 58:1198-11207. http://dx.doi.org/10.1093/jac/dkl396.
15. Rudramurthy SM, Chakrabarti A, Geertsen E, Mouton JW, Meis JF. 2011. In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Diagn. Microbiol. Infect. Dis. 71:370-377. http://dx.doi.org/10.1016/j. diagmicrobio.2011.08.006.
16. Seifert H, Aurbach U, Stefanik D, Cornely O. 2007. In vitro activities of isavuconazole and other antifungal agents against Candida bloodstream isolates. Antimicrob. Agents Chemother. 51:1818-1821. http://dx.doi.org/10.1128/AAC. 01217-06. (Pubitemid 46744163)
17. Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. 2008. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob. Agents Chemother. 52:1396-1400. http://dx.doi.org/10.1128/AAC.01512-07. (Pubitemid 351522004)
18. Yamazaki T, Inagaki Y, Fujii T, Ohwada J, Tsukazaki M, Umeda I, Kobayashi K, Shimma N, Page MG, Arisawa M. 2010. In vitro activity of isavuconazole against 140 reference fungal strains and 165 clinically isolated yeasts from Japan. Int. J. Antimicrob. Agents 36:324-331. http://dx.doi.org/10.1016/j. ijantimicag.2010.06.003.
19. Thompson GR, III, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. 2009. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53:309-311. http://dx.doi.org/10.1128/AAC.01216-08.
20. Illnait-Zaragozi MT, Martinez GF, Curfs-Breuker I, Fernandez CM, Boekhout T, Meis JF. 2008. In vitro activity of the new azole isavuconazole (BAL4815) compared with six other antifungal agents against 162 Cryptococcus neoformans isolates from Cuba. Antimicrob. Agents Chemother. 52:1580-1582. http://dx.doi.org/10.1128/AAC.01384-07. (Pubitemid 351522042)
21. Chakrabarti A, Shivaprakash MR, Curfs-Breuker I, Baghela A, Klaassen CH, Meis JF. 2010. Apophysomyces elegans: epidemiology, amplified fragment length polymorphism typing, and in vitro antifungal susceptibility pattern. J. Clin. Microbiol. 48:4580-4585. http://dx.doi.org/10.1128/JCM.01420-10.
22. Verweij PE, Gonzalez GM, Wiedrhold NP, Lass-Florl C, Warn P, Heep M, Ghannoum MA, Guinea J. 2009. In vitro antifungal activity of isavuconazole against 345 Mucorales isolates collected at study centers in eight countries. J. Chemother. 21:272-281. http://dx.doi.org/10.1179/joc.2009.21.3.272.
23. Ribes JA, Vanover-Sams CL, Baker DJ. 2000. Zygomycetes in human disease. Clin. Microbiol. Rev. 13:236-301. http://dx.doi.org/10.1128/CMR.13.2.236-301. 2000. (Pubitemid 30205427)
24. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH, Kontoyiannis DP, Walsh TJ. 2005. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin. Infect. Dis. 41:634-653. http://dx.doi.org/10.1086/432579. (Pubitemid 41170352)
25. Abe A, Oda Y, Asano K, Sone T. 2007. Rhizopus delemar is the proper name for Rhizopus oryzae fumaric-malic acid producers. Mycologia 99:714-722. http://dx.doi.org/10.3852/mycologia.99.5.714.
26. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Document M38-A2. CLSI, Wayne, PA.
27. Luo G, Gebremariam T, Lee H, French SW, Wiederhold NP, Patterson TF, Filler SG, Ibrahim AS. 2013. Efficacy of liposomal amphotericin B and posaconazole in intratracheal models of murine mucormycosis. Antimicrob. Agents Chemother. 57:3340-3347. http://dx.doi.org/10.1128/AAC.00313-13.
28. Ibrahim AS, Avanessian V, Spellberg B, Edwards JE, Jr. 2003. Liposomal amphotericin B, and not amphotericin B deoxycholate, improves survival of diabetic mice infected with Rhizopus oryzae. Antimicrob. Agents Chemother. 47:3343-3344. http://dx.doi.org/10.1128/AAC.47.10.3343-3344.2003. (Pubitemid 37229602)
29. Ibrahim AS, Bowman JC, Avanessian V, Brown K, Spellberg B, Edwards JE, Jr, Douglas CM. 2005. Caspofungin inhibits Rhizopus oryzae 1,3-beta-D-glucan synthase, lowers burden in brain measured by quantitative PCR, and improves survival at a low but not a high dose during murine disseminated zygomycosis. Antimicrob. Agents Chemother. 49:721-727. http://dx.doi.org/10.1128/AAC.49.2. 721-727.2005. (Pubitemid 40175685)
30. Lepak AJ, Marchillo K, Vanhecker J, Diekema D, Andes DR. 2013. Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model. Antimicrob. Agents Chemother. 57:5642-5648. http://dx.doi.org/10.1128/AAC.01354-13.
31. Schmitt-Hoffmann A, Roos B, Heep M, Schleimer M, Weidekamm E, Brown T, Roehrle M, Beglinger C. 2006. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob. Agents Chemother. 50:279-285. http://dx.doi.org/10.1128/AAC.50.1.279-285.2006. (Pubitemid 43042933)
32. Majithiya J, Sharp A, Parmar A, Denning DW, Warn PA. 2009. Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei. J. Antimicrob. Chemother. 63:161-166. http://dx.doi.org/10.1093/jac/dkn431.
33. Warn PA, Sharp A, Parmar A, Majithiya J, Denning DW, Hope WW. 2009. Pharmacokinetics and pharmacodynamics of a novel triazole, isavuconazole: mathematical modeling, importance of tissue concentrations, and impact of immune status on antifungal effect. Antimicrob. Agents Chemother. 53:3453-34561. http://dx.doi.org/10.1128/AAC.01601-08.
34. Bowman JC, Abruzzo GK, Anderson JW, Flattery AM, Gill CJ, Pikounis VB, Schmatz DM, Liberator PA, Douglas CM. 2001. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. 45:3474-3481. http://dx.doi.org/10.1128/AAC.45.12.3474-3481.2001. (Pubitemid 33107865)